FDA Approves JNJ’s Darzalex in Combination with VMP
Johnson & Johnson’s (JNJ) Darzalex injection is a CD-38 surface protein–directed antibody approved for the treatment of multiple myeloma. Today, JNJ announced that the US Food & Drug Administration (or FDA) approved Darzalex in combination with other drugs for the treatment of multiple myeloma, marking the fifth indication for which Darzalex has FDA approval.